1370451-47-0

Basic information

• Product Name: C₉H₁₀N₂O₅S
• Synonyms: C₉H₁₀N₂O₅S
• CAS NO: 1370451-47-0
• Molecular Weight: 258.255
• Mol File: 1370451-47-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₉H₁₀N₂O₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₉H₁₀N₂O₅S(1370451-47-0)
• EPA Substance Registry System: C₉H₁₀N₂O₅S(1370451-47-0)

Safety Data

• Hazardous Substances Data: 1370451-47-0(Hazardous Substances Data)

Upstream product

• 1050514-15-2 2-(4-methoxy-2-nitrophenylsulfonylamino)ethanol 
• 1370451-32-3 2-(4-methoxy-2-nitrophenylsulfonylamino)ethyl methanesulfonate 

Downstream Products

• 1370451-44-7 1-[2-(2-amino-4-methoxyphenylsulfonylamino)ethyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 1370451-38-9 1-[2-(4-methoxy-2-nitrophenylsulfonylamino)ethyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 122555-91-3 1,4,7-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane 

Relevant articles and documents

Development of hypoxia-sensitive Gd3+-based MRI contrast agents

Hypoxia occurs in various diseases, including cancer, ischemia, and acute and chronic vascular diseases. Here we describe the design and synthesis of the first hypoxia-sensitive MRI contrast agents, SAGds. SAGds showed a pH-dependent r1 relaxivity change associated with intramolecular chelation of the nitrogen atom of the sulfonamide moiety to the Gd3+ center. There was a correlation between the pKa of the r1 relaxivity change and the sum of the Hammett σ constants of substituents on the aromatic ring. Among the synthesized compounds, 4NO22MeOSAGd was selectively reduced to the amine by rat liver microsomes under hypoxic conditions, resulting in a 1.8-fold increment of the r1 relaxivity owing to the change in pKa of the arylsulfonamide moiety. This enhancement of the r 1 relaxivity could be clearly detected in T1-weighted MR images. Thus, 4NO22MeOSAGd is a 'smart' MRI contrast agent for the detection of hypoxia under physiological conditions.